A newsletter from PATH


  Like this newsletter on Facebook  Tweet about this newsletter





Quality assurance materials for onchocerciasis and lymphatic filariasis tests

PATH and the Senegal Ministry of Health conducted a study with the Ov16 rapid test to compare against skin snip microscopy for onchocerciasis surveillance. Technicians were trained using quality assurance materials developed by PATH. Photo: PATH/K. Barrett

PATH Diagnostics has developed a set of materials for organizing a quality assurance (QA) program to support use of rapid diagnostic tests for onchocerciasis and lymphatic filariasis (LF). A well-functioning QA program is necessary to achieve high-quality results required by surveillance programs tracking toward disease elimination. PATH has developed videos, user guides, and forms to instruct users on training, proficiency, QA and daily quality control (QC) panels for the Ov16 and Wb123 monoplex rapid tests and the Ov16/Wb123 biplex test.

Access the QA program materials here in English and in French; contact dxinfo@path.org to request training, proficiency, and QA panels, and positive and negative QC samples.


Interview with Dr. Monique Dorkenoo, Coordinator of the Togo LF National Program


Photo: M. Dorkenoo


We spoke with Dr. Monique Dorkenoo, Coordinator of the Lymphatic Filariasis National Program at the Togo Ministry of Health, to learn more about how new rapid tests for onchocerciasis and LF could change the game for surveillance of both diseases in the field. You can read the full interview here.


New diagnostic gap reports on IDM NTDs

PATH/J. Jacobson

PATH has completed a series of diagnostic gap reports on four neglected tropical diseases requiring innovative and intensive disease management (known as IDM NTDs): human African trypanosomiasis, leprosy, visceral leishmaniasis, and Chagas disease [PDFs]. With the input of key stakeholders and partners, PATH assessed needs and landscaped potential solutions for improving availability, access, and adoption of diagnostic tools for IDM NTDs. All four reports can be found here.


Sample panels for aiding development of new diagnostics

Blood samples with varying levels of malaria parasitemia. PATH/H. White

PATH has created sample panels [PDF] that will support development of new diagnostics for a number of infectious diseases, including malaria, HIV, tetanus and tuberculosis. More than 18,000 individual samples have been created in common specimens such as serum, stool, plasma, and blood. These samples are available to diagnostic developers for use in test development evaluations after approval by the Bill & Melinda Gates Foundation and completion of a material transfer agreement. For more information about accessing the sample panels, email dxinfo@path.org.

View the diagnostic sample panel fact sheet. [PDF]





July 2016 - Issue 4













We value your feedback. Please contact us with what you would like to see featured, interesting news from your organization, and any questions or comments you have at dxinfo@path.org.

Previous issues of DxNEWS



PATH - A catalyst for global health


PO Box 900922 |
Seattle, WA 98109 USA
2201 Westlake Avenue, Suite 200 |
Seattle, WA 98121 USA
Tel: 206.285.3500 |
Fax: 206.285.6619
www.path.org |


   Like this newsletter on Facebook


   Tweet about this newsletter